Mental Health
|
December 16, 2024

How Ketamine Therapy May Work for Mental Health and Pain Management

Written By
Dr. Kaylan Jackson Ph.D.
Medically Reviewed by
Updated On
December 23, 2024

In recent years, ketamine therapy has gained attention as a revolutionary treatment for mental health disorders and chronic pain conditions. Originally developed as an anesthetic, ketamine has emerged as a potential option for people managing conditions like treatment-resistant depression, post-traumatic stress disorder (PTSD), and fibromyalgia

This guide explores everything you need to know about ketamine therapy: its history, how it works, benefits, risks, costs, and how to determine if it’s the right option for you or your patients.

[signup]

What Is Ketamine Therapy?

Ketamine was approved by the FDA in 1970 as a safe anesthetic for humans and animals. Its ability to induce a dissociative state made it an effective option for surgeries and emergency procedures, particularly in field hospitals during the Vietnam War. 

Over the years, researchers observed its potential mood-stabilizing effects in patients with depression and chronic pain.

In the 2000s, clinical studies confirmed ketamine’s ability to provide relief for patients with treatment-resistant depression and other mental health conditions. These discoveries fueled the development of ketamine infusion clinics and the approval of esketamine, a nasal spray derived from ketamine.

Why Is Ketamine Therapy Unique?

Traditional mental health treatments, such as selective serotonin reuptake inhibitors (SSRIs), work by gradually altering neurotransmitter levels like serotonin. This process can take weeks or months to show results, and for some patients, these treatments don’t work at all. Ketamine therapy, by contrast:

  • Works directly on the glutamate system, a key neurotransmitter involved in brain plasticity and emotional regulation.
  • May provide rapid relief, with some patients reporting improvement within hours of their first treatment.
  • Can help reset pain and mood pathways, offering long-term benefits for both mental health and chronic pain.

Understanding these differences can help patients and practitioners appreciate why ketamine therapy is so transformative.

How Ketamine Therapy Works

To grasp how ketamine achieves its powerful effects, it’s helpful to explore the science behind its action in the brain.

Ketamine’s Mechanism of Action

Ketamine’s therapeutic effects stem from its ability to block N-methyl-D-aspartate (NMDA) receptors in the brain. These receptors are involved in how neurons communicate and regulate mood, memory, and pain perception. By inhibiting NMDA receptors, ketamine:

This mechanism may help alleviate symptoms and address neurological disruptions potentially linked to conditions like depression or PTSD.

Types of Ketamine Therapy

With so many ways to administer ketamine, how do you know which one might be right for you? Let’s break it down.

Ketamine therapy is delivered in various forms, depending on the patient’s needs and the condition being treated:

1. Intravenous (IV) Infusion

  • The gold standard for ketamine therapy.
  • Administered in a clinic under medical supervision, offering precise dosage control.
  • May provide consistent and rapid results for some patients.

2. Nasal Spray (esketamine)

  • FDA-approved for treatment-resistant depression.
  • Convenient and non-invasive to administer, but may require more frequent dosing.

3. Intramuscular (IM) Injection

4. Oral Administration

  1. Used primarily for at-home maintenance therapy.
  2. Absorption rates vary, and effects are typically less consistent.

Each method has pros and cons, with IV infusions being the most commonly recommended option for severe cases due to their immediate and potent effects.

Benefits of Ketamine Therapy

For many patients, ketamine therapy represents a beacon of hope when other treatments have failed.

Rapid Relief for Depression

Ketamine is most widely known for its success in treating treatment-resistant depression (TRD)

  • Studies suggest that up to 70% of patients with TRD may experience significant improvements after ketamine therapy.
  • Unlike SSRIs, which can take weeks to build up in the system, ketamine’s effects are often felt within hours. This makes it a critical tool for individuals at risk of suicide or severe emotional distress.

PTSD and Anxiety Disorders

For patients with post-traumatic stress disorder (PTSD) or anxiety, ketamine offers a way to reduce symptoms that traditional therapies often fail to address. 

  • By calming overactive neural pathways, ketamine helps patients gain clarity and process trauma more effectively. 
  • Emerging research suggests it may also reduce fear-based responses by targeting the amygdala, the brain’s fear-processing center.

Chronic Pain Management

Ketamine’s analgesic properties make it highly effective for chronic pain conditions, including:

Unlike opioids, which can lead to dependency and tolerance, ketamine may work by modulating the brain’s pain pathways. This reduces the perception of pain and can provide lasting relief even after therapy sessions end.

What to Expect During Ketamine Therapy

Understanding what happens before, during, and after a ketamine session can help alleviate concerns and prepare patients for the experience.

Pre-Treatment Evaluation

Before starting ketamine therapy, a thorough medical and psychological assessment is conducted. This evaluation determines:

  • Suitability for ketamine therapy.
  • Any contraindications, such as heart disease, substance abuse, or certain psychiatric conditions.
  • Potential interactions with current medications.

Patients may need to stop taking certain medications, such as benzodiazepines, which can interfere with ketamine’s effectiveness.

During a Session

Here’s what typically happens during a session:

Post-Treatment and Follow-Up

After the session, patients are observed for about 30 minutes to an hour to ensure they’ve returned to baseline. Follow-up visits allow clinicians to assess progress and adjust treatment plans. Patients may benefit from integrating therapy or counseling to process insights gained during their ketamine sessions.

Risks and Side Effects of Ketamine Therapy

It’s natural to worry about side effects or risks, but in a clinical setting with experienced professionals, ketamine therapy is remarkably safe. Still, no treatment is without risks, and understanding ketamine’s potential side effects can help patients make informed decisions.

Common Side Effects

While ketamine is generally well-tolerated, it can cause temporary side effects, such as:

Serious Risks

Rare but serious risks include:

  • Dependency: While unlikely in a clinical setting, misuse outside medical supervision can lead to addiction.
  • Cognitive Effects: Long-term, high-dose use may affect memory or cognitive function.
  • Cardiovascular Concerns: Patients with uncontrolled high blood pressure or heart conditions may experience complications.

Clinics generally follow strict safety protocols to minimize these risks, including pre-screening and continuous monitoring during treatment.

Who Should Avoid Ketamine Therapy?

Ketamine therapy may not be suitable for everyone. Specific contraindications include:

  • Uncontrolled high blood pressure: The treatment can temporarily raise blood pressure, posing risks for patients with cardiovascular concerns.
  • Active psychosis: Ketamine’s dissociative effects may worsen symptoms in individuals experiencing psychosis or certain forms of bipolar disorder.
  • Pregnancy and breastfeeding: The effects of ketamine on fetal and infant health are not well studied, so it is typically avoided during pregnancy and breastfeeding.
  • Substance abuse: Those actively misusing substances or at high risk for addiction may need alternative treatments or additional support.

Patients with any of these conditions should work closely with a healthcare provider to explore safer options.

Safety Measures and Professional Oversight

The controlled environment of a medical clinic is key to the safe administration of ketamine therapy. Here’s how clinics prioritize patient safety:

  • Pre-Treatment Screening: Patients undergo thorough evaluations to identify any contraindications or risks, including a review of their medical history, medications, and current health status.
  • Monitoring During Treatment: Throughout the session, clinicians monitor vital signs, such as heart rate, oxygen levels, and blood pressure, to ensure safety and address side effects promptly.
  • Emergency Protocols: Clinics are equipped to manage rare complications, such as severe dissociation or allergic reactions, ensuring that patients remain in good hands.

These measures underscore why ketamine therapy should only be performed in medically supervised settings.

Comparing Ketamine Therapy to Traditional Treatments

Ketamine therapy stands out for its rapid onset and unique approach, but how does it compare to more traditional treatments like SSRIs, psychotherapy, or electroconvulsive therapy (ECT)? Understanding these differences can help patients and practitioners make informed decisions.

Ketamine vs. Antidepressants

Ketamine offers several advantages over conventional antidepressants:

  • Onset of Relief: While SSRIs and other antidepressants often take weeks or even months to produce noticeable effects, ketamine can provide relief within hours to days. This is particularly important for individuals experiencing severe depression or suicidal thoughts.
  • Treatment-Resistant Cases: Many patients who do not respond to SSRIs or serotonin-based therapies find success with ketamine, as it works through entirely different pathways in the brain.
  • Improved Quality of Life: By targeting glutamate and promoting neuroplasticity, ketamine may support the repair of neural connections potentially affected by stress or trauma, which could contribute to emotional and mental health improvements.

However, antidepressants are generally more affordable, covered by insurance, and can be used as maintenance therapy without requiring regular clinic visits.

Ketamine vs. ECT and TMS

For severe or treatment-resistant depression, ketamine therapy is often compared to electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS):

  • Invasiveness: ECT involves inducing seizures under anesthesia, which can lead to side effects like memory loss. TMS, while noninvasive, requires daily sessions over several weeks. Ketamine, by contrast, is minimally invasive and typically involves a manageable schedule of infusions or sprays.
  • Effectiveness: Studies suggest ketamine works faster than both ECT and TMS in alleviating symptoms, making it a preferred option for patients in crisis.
  • Side Effects: While ECT and TMS have their own side effect profiles, ketamine’s side effects—like dissociation or nausea—are short-lived and tend to resolve quickly after treatment.

Cost and Accessibility of Ketamine Therapy

Understanding the financial and logistical aspects of ketamine therapy can help patients prepare for treatment.

Treatment Costs

Most patients require an initial series of 6–8 treatments, followed by maintenance sessions every few weeks or months. The cost of ketamine therapy varies depending on the method of administration and clinic location:

Insurance and Financial Assistance

Esketamine, the FDA-approved nasal spray, is more likely to be covered by insurance. IV ketamine therapy is often paid out-of-pocket, but some clinics may offer payment plans or sliding scale fees to improve accessibility.

FAQs 

How Long Do the Effects Last? For depression, the effects can last 1–2 weeks after a single session. Maintenance sessions are often spaced out to prolong benefits.

Can Ketamine Be Combined with Other Treatments? Yes, ketamine is often used alongside psychotherapy, traditional medications, or mindfulness practices to maximize results.

How Do I Choose a Reputable Clinic? Look for clinics with licensed professionals, clear treatment protocols, and positive patient reviews.

[signup]

Key Takeaways

  • Ketamine therapy may provide rapid relief for depression, PTSD, and chronic pain, particularly for patients who have not responded to traditional treatments.
  • Its mechanism of action promotes neuroplasticity, helping the brain heal and adapt.
  • Administered in safe, monitored environments, ketamine has a strong safety profile with manageable side effects.
  • Costs can be high, but options like esketamine nasal spray may offer insurance coverage.
  • Always consult with a qualified provider to determine whether ketamine therapy is right for you.

If you or someone you know is struggling with mental health challenges or chronic pain, consult a healthcare provider to determine whether ketamine therapy may be an appropriate option.

The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.

Learn more

No items found.

Lab Tests in This Article

No lab tests!

Abdallah, C. G., Averill, L. A., Akiki, T. J., Raza, M., Averill, C. L., Gomaa, H., … Krystal, J. H. (2019). The neurobiology and pharmacotherapy of posttraumatic stress disorder. Annual Review of Pharmacology and Toxicology, 59(1), 171–189. https://doi.org/10.1146/annurev-pharmtox-010818-021701

Ahern, T. L., Herring, A. A., Miller, S., & Frazee, B. W. (2015). Low-Dose Ketamine Infusion for Emergency Department Patients with Severe Pain. Pain Medicine, 16(7), 1402–1409. https://doi.org/10.1111/pme.12705

Andrade, C. (2019). Oral Ketamine for Depression, 2. The Journal of Clinical Psychiatry, 80(2). https://doi.org/10.4088/jcp.19f12838

Andrashko, V., Novak, T., Brunovsky, M., Klirova, M., Sos, P., & Horacek, J. (2020). The Antidepressant Effect of Ketamine Is Dampened by Concomitant Benzodiazepine Medication. Frontiers in Psychiatry, 11. https://doi.org/10.3389/fpsyt.2020.00844

Aslam, A. (2024). Practice Patterns and Medical Provider Perceptions of Ketamine in the Treatment of Psychiatric Disorders: A Nationwide Survey. Retrieved December 11, 2024, from Proquest.com website: https://search.proquest.com/openview/3f84d5e3e9b6e85d5ad141c5c3548499/1?pq-origsite=gscholar&cbl=18750&diss=y

Ballantyne, J. C., & LaForge, S. K. (2007). Opioid dependence and addiction during opioid treatment of chronic pain. Pain, 129(3), 235–255. https://doi.org/10.1016/j.pain.2007.03.028

Beaudoin, F. L., Lin, C., Guan, W., & Merchant, R. C. (2014). Low‐dose Ketamine Improves Pain Relief in Patients Receiving Intravenous Opioids for Acute Pain in the Emergency Department: Results of a Randomized, Double‐blind, Clinical Trial. Academic Emergency Medicine, 21(11), 1193–1202. https://doi.org/10.1111/acem.12510

Becker, J. (2014). Regarding the Transpersonal Nature of Ketamine Therapy: An Approach to the Work. International Journal of Transpersonal Studies, 33(2), 151–159. https://doi.org/10.24972/ijts.2014.33.2.151

Blonk, M. I., Koder, B. G., van den Bemt, P. M. L. A., & Huygen, F. J. P. M. (2010). Use of oral ketamine in chronic pain management: A review. European Journal of Pain, 14(5), 466–472. https://doi.org/10.1016/j.ejpain.2009.09.005

Chen, Y., Gu, H., Li, W., & Chen, Y. (2024). A real-world pharmacovigilance study of esketamine nasal spray. Medicine, 103(36), e39484–e39484. https://doi.org/10.1097/md.0000000000039484

Christensen, A., & Pruskowski, J. (2020). The Role of Ketamine in Depression #384. Journal of Palliative Medicine, 23(1), 136–138. https://doi.org/10.1089/jpm.2019.0496

Clements, J. A., Nimmo, W. S., & Grant, I. S. (1982). Bioavailability, Pharmacokinetics, and Analgesic Activity of Ketamine in Humans. Journal of Pharmaceutical Sciences, 71(5), 539–542. https://doi.org/10.1002/jps.2600710516

Cloyd, J. (2023, March 15). The relationship between the sleep stress cycle. Retrieved from Rupa Health website: https://www.rupahealth.com/post/the-relationship-between-the-sleep-stress-cycle

Cloyd, J. (2024, June 6). 3 Foods to Avoid for Improved Cortisol Levels. Retrieved from Rupa Health website: https://www.rupahealth.com/post/cortisol-foods-to-avoid

Conner, V. (2022, September 13). Fibromyalgia: Causes, Symptoms, & Alternative Treatments. Retrieved from Rupa Health website: https://www.rupahealth.com/post/fibromyalgia-causes-symptoms-treatments

Craven, R. (2007). Ketamine. Anaesthesia, 62(s1), 48–53. https://doi.org/10.1111/j.1365-2044.2007.05298.x

Creedon, K. (2022, July 14). Simple lifestyle changes that can help keep high blood pressure under control. Retrieved from Rupa Health website: https://www.rupahealth.com/post/simple-lifestyle-changes-that-can-help-control-high-blood-pressure

Crisp, T., Perrotti, J. M., Smith, D. F., Stafinsky, J. L., & Smith, D. (1991). The local monoaminergic dependency of spinal ketamine. European Journal of Pharmacology, 194(2-3), 167–172. https://doi.org/10.1016/0014-2999(91)90101-u

d’Andrea, G., Pettorruso, M., Lorenzo, G. D., Mancusi, G., McIntyre, R. S., & Martinotti, G. (2023). Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties? European Neuropsychopharmacology, 70, 49–55. https://doi.org/10.1016/j.euroneuro.2023.02.010

Dakwar, E., Nunes, E. V., Hart, C. L., Foltin, R. W., Mathew, S. J., Carpenter, K. M., … Levin, F. R. (2019). A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. American Journal of Psychiatry, 176(11), 923–930. https://doi.org/10.1176/appi.ajp.2019.18101123

Das, J. (2020). Repurposing of Drugs–The Ketamine Story. Journal of Medicinal Chemistry, 63(22), 13514–13525. https://doi.org/10.1021/acs.jmedchem.0c01193

de la Salle, S., Choueiry, J., Shah, D., Bowers, H., McIntosh, J., Ilivitsky, V., & Knott, V. (2016). Effects of Ketamine on Resting-State EEG Activity and Their Relationship to Perceptual/Dissociative Symptoms in Healthy Humans. Frontiers in Pharmacology, 7. https://doi.org/10.3389/fphar.2016.00348

DePorto, T. (2022, December 9). Worried About Heart Disease? Ask Your Provider for These 6 Specialty Labs at Your Next Appointment. Retrieved from Rupa Health website: https://www.rupahealth.com/post/worried-about-heart-disease-ask-your-provider-for-these-6-specialty-labs-at-your-next-appointment

DePorto, T. (2023, January 25). Top Nutrient Deficiencies That Affect Mental Health. Retrieved from Rupa Health website: https://www.rupahealth.com/post/top-nutrient-deficiencies-that-affect-mental-health

Ding, Z., & White, P. F. (2002). Anesthesia for Electroconvulsive Therapy. Anesthesia & Analgesia, 94(5), 1351–1364. https://doi.org/10.1097/00000539-200205000-00057

Diorio, B. (2023, February 21). What is Integrative Medicine Pain Management? Retrieved from Rupa Health website: https://www.rupahealth.com/post/what-is-integrative-medicine-pain-management

Endler, N. S. (1988). The Origins of Electroconvulsive Therapy (ECT). The Journal of ECT, 4(1), 5. Retrieved from https://journals.lww.com/ectjournal/Abstract/1988/04010/The_Origins_of_Electroconvulsive_Therapy__ECT_.3.aspx

Fava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., … Papakostas, G. I. (2018). Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry, 25(7). https://doi.org/10.1038/s41380-018-0256-5

Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lançon, C., Brittner, M., … Boyer, L. (2014). Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology, 231(18), 3663–3676. https://doi.org/10.1007/s00213-014-3664-5

Gibbons, R., Hur, K., Hendricks Brown, Davis, J., & Mann. (2012). Benefits From Antidepressants Synthesis of 6-Week Patient-Level Outcomes From Double-blind Placebo-Controlled Randomized Trials of Fluoxetine and Venlafaxine. Arch Gen Psychiatry, 69(6), 572–579. https://doi.org/10.1001/archgenpsychiatry.2011.2044

Glutamate | Rupa Health. (2020). Retrieved December 11, 2024, from Rupa Health website: https://www.rupahealth.com/biomarkers/glutamate

Haile, C. N., Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Foulkes, A., … Mathew, S. J. (2013). Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. The International Journal of Neuropsychopharmacology, 17(02), 331–336. https://doi.org/10.1017/s1461145713001119

Hyttel, J. (1994). Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). International Clinical Psychopharmacology, 9, 19–26. Retrieved from https://journals.lww.com/intclinpsychopharm/Abstract/1994/03001/Pharmacological_characterization_of_selective.4.aspx

Ingram, R., Kang, H., Lightman, S., Jane, D. E., Bortolotto, Z. A., Collingridge, G. L., … Volianskis, A. (2018). Some distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity. Neuropharmacology, 142, 30–40. https://doi.org/10.1016/j.neuropharm.2018.06.008

Ionescu, D. F., Luckenbaugh, D. A., Niciu, M. J., Richards, E. M., & Zarate, C. A. (2014). A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disorders, 17(4), 438–443. https://doi.org/10.1111/bdi.12277

Jouguelet-Lacoste, J., La Colla, L., Schilling, D., & Chelly, J. E. (2015). The Use of Intravenous Infusion or Single Dose of Low-Dose Ketamine for Postoperative Analgesia: A Review of the Current Literature. Pain Medicine, 16(2), 383–403. https://doi.org/10.1111/pme.12619

Keith, K. M., Geller, J., Froehlich, A., Arfken, C., Oxley, M., & Mischel, N. (2022). Vital Sign Changes During Intravenous Ketamine Infusions for Depression. Journal of Clinical Psychopharmacology, 42(3), 254–259. https://doi.org/10.1097/jcp.0000000000001542

Khakham, C. (2023a, April 18). Psychedelic Therapy for Mental Health: What You Need To Know in 2023. Retrieved from Rupa Health website: https://www.rupahealth.com/post/psychedelic-therapy-for-mental-health-what-you-need-to-know-in-2023

Khakham, C. (2023b, May 19). A Comprehensive Review of Complementary and Integrative Treatments of Fibromyalgia: Testing, Supplements, and Therapies. Retrieved from Rupa Health website: https://www.rupahealth.com/post/a-comprehensive-review-of-complementary-and-integrative-approaches-to-treatments-of-fibromyalgia-testing-supplements-and-therapies

Khakham, C. (2023c, July 28). Top Labs To Run Bi-Annually On Your Depression Patients. Retrieved from Rupa Health website: https://www.rupahealth.com/post/top-labs-to-run-bi-annually-on-your-depression-patients

Kresge, K. (2023a, January 31). An Integrative Approach to Mental Health. Retrieved from Rupa Health website: https://www.rupahealth.com/post/an-integrative-approach-to-mental-health

Kresge, K. (2023b, February 21). An Integrative Medicine Approach to Depression. Retrieved from Rupa Health website: https://www.rupahealth.com/post/an-integrative-medicine-approach-to-depression

Lahti, A. (1995). Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia. Neuropsychopharmacology, 13(1), 9–19. https://doi.org/10.1016/0893-133x(94)00131-i

LeDoux, J. (2007). The amygdala. Current Biology, 17(20), R868–R874. https://doi.org/10.1016/j.cub.2007.08.005

Levinta, A., Meshkat, S., McIntyre, R. S., Ho, C., Lui, L. M. W., Lee, Y., … Rosenblat, J. D. (2022). The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic review. Journal of Affective Disorders, 318, 139–149. https://doi.org/10.1016/j.jad.2022.08.050

Luber, B., & Lisanby, S. H. (2014). Enhancement of human cognitive performance using transcranial magnetic stimulation (TMS). NeuroImage, 85, 961–970. https://doi.org/10.1016/j.neuroimage.2013.06.007

Maes, M. (2001). The immunoregulatory effects of antidepressants. Human Psychopharmacology: Clinical and Experimental, 16(1), 95–103. https://doi.org/10.1002/hup.191

Maholy, N. (2023, February 17). A functional medicine approach to anxiety: Testing, nutrition, & supplements. Retrieved from Rupa Health website: https://www.rupahealth.com/post/a-functional-medicine-approach-to-anxiety

Mathew, S. J., Shah, A., Lapidus, K., Clark, C., Jarun, N., Ostermeyer, B., & Murrough, J. W. (2012). Ketamine for Treatment-Resistant Unipolar Depression. CNS Drugs, 26(3), 189–204. https://doi.org/10.2165/11599770-000000000-00000

McMurray, L. A., & Deren, B. (2019). Neuromodulation Interventions: ECT and rTMS – Work-Up, Preparation, and Posttreatment Care + Ketamine in Inpatient Psychiatry. Inpatient Geriatric Psychiatry, 293–323. https://doi.org/10.1007/978-3-030-10401-6_16

Mion, G. (2017, September). September 2017 - Volume 34 - Issue 9 : European Journal of Anaesthesiology | EJA. Retrieved from journals.lww.com website: https://journals.lww.com/ejanaesthesiology/Fulltext/2017/09000/History_of_anaesthesia__The_ketamine_story___past

Morgan, C. J. A., Muetzelfeldt, L., & Curran, H. V. (2009). Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction, 104(1), 77–87. https://doi.org/10.1111/j.1360-0443.2008.02394.x

Muetzelfeldt, L., Kamboj, S. K., Rees, H., Taylor, J., Morgan, C. J. A., & Curran, H. V. (2008). Journey through the K-hole: Phenomenological aspects of ketamine use. Drug and Alcohol Dependence, 95(3), 219–229. https://doi.org/10.1016/j.drugalcdep.2008.01.024

Oats, J. N., Vasey, D. P., & Waldron, B. (1979). EFFECTS OF KETAMINE ON THE PREGNANT UTERUS. British Journal of Anaesthesia, 51(12), 1163–1166. https://doi.org/10.1093/bja/51.12.1163

Orser, Beverley A., Pennefather, Peter S., & MacDonald, John F. (1997). Multiple Mechanisms of Ketamine Blockade of N-methyl-D-aspartate Receptors . Anesthesiology, 86(4), 903–917. https://doi.org/10.1097/00000542-199704000-00021

Parikh, S. V., Lopez, D., Vande Voort, J. L., Rico, J., Achtyes, E., Coryell, W., … Bio-K Study Team. (2021). Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer. Psychopharmacology Bulletin, 51(3), 109–124. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374924/

Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016). Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Clinical Pharmacokinetics, 55(9), 1059–1077. https://doi.org/10.1007/s40262-016-0383-6

Powers III, A. R., Gancsos, M. G., Finn, E. S., Morgan, P. T., & Corlett, P. R. (2015). Ketamine-Induced Hallucinations. Psychopathology, 48(6), 376–385. https://doi.org/10.1159/000438675

Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., … Nemeroff, C. B. (2017). A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry, 74(4), 399. https://doi.org/10.1001/jamapsychiatry.2017.0080

Sassano-Higgins, S., Baron, D., Juarez, G., Esmaili, N., & Gold, M. (2016). A REVIEW OF KETAMINE ABUSE AND DIVERSION. Depression and Anxiety, 33(8), 718–727. https://doi.org/10.1002/da.22536

Serotonin. (n.d.). Retrieved from Rupa Health website: https://www.rupahealth.com/biomarkers/serotonin

Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018). Side-effects associated with ketamine use in depression: a systematic review. The Lancet Psychiatry, 5(1), 65–78. https://doi.org/10.1016/s2215-0366(17)30272-9

Singh, J. B., Daly, E. J., Mathews, M., Fedgchin, M., Popova, V., Hough, D., & Drevets, W. C. (2020). Approval of esketamine for treatment-resistant depression. The Lancet Psychiatry, 7(3), 232–235. https://doi.org/10.1016/s2215-0366(19)30533-4

Smart, K. M., Ferraro, M. C., Wand, B. M., & O’Connell, N. E. (2022). Physiotherapy for pain and disability in adults with complex regional pain syndrome (CRPS) types I and II. Cochrane Database of Systematic Reviews, 2022(5). https://doi.org/10.1002/14651858.cd010853.pub3

Souery, D., Papakostas, G., & Trivedi, M. (2006). Treatment-Resistant Depression. Retrieved from https://www.psychiatrist.com/read-pdf/21622/

Szarmach, J., Cubała, W. J., Włodarczyk, A., & Gałuszko-Węgielnik, M. (2020). Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression. Neuropsychiatric Disease and Treatment, Volume 16, 2539–2551. https://doi.org/10.2147/ndt.s273287

Tamman, A., Anand, A., & Mathew, S. J. (2022). A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression. Expert Opinion on Drug Safety, 1–15. https://doi.org/10.1080/14740338.2022.2049754

Teeple, A., Maryia Zhdanava, Pilon, D., Caron-Lapointe, G., Lefèbvre, P., & Joshi, K. (2023). Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance. Current Medical Research and Opinion, 39(8), 1167–1174. https://doi.org/10.1080/03007995.2023.2239045

Teeter, L. A. (2023, May 2). An Integrative and Functional Nutrition Approach to Substance Abuse and Recovery. Retrieved from Rupa Health website: https://www.rupahealth.com/post/an-integrative-and-functional-nutrition-approach-to-substance-abuse-and-recovery

Tiger, M., Veldman, E. R., Ekman, C.-J., Halldin, C., Svenningsson, P., & Lundberg, J. (2020). A randomized placebo-controlled PET study of ketamine´s effect on serotonin1B receptor binding in patients with SSRI-resistant depression. Translational Psychiatry, 10(1). https://doi.org/10.1038/s41398-020-0844-4

Willis, D. E., & Goldstein, P. A. (2022). Targeting Affective Mood Disorders With Ketamine to Prevent Chronic Postsurgical Pain. Frontiers in Pain Research, 3. https://doi.org/10.3389/fpain.2022.872696

Willyard, C. (2022). Psychedelic drugs take on depression. Nature, 608(7924), S36–S38. https://doi.org/10.1038/d41586-022-02205-w

Wolfson, P., Cole, R., Lynch, K., Yun, C., Wallach, J., Andries, J., & Whippo, M. (2022). The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of Ketamine and Metabolites. Journal of Psychoactive Drugs, 1–5. https://doi.org/10.1080/02791072.2022.2101903

Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022). Ketamine treatment for depression: a review. Discover Mental Health, 2(1). https://doi.org/10.1007/s44192-022-00012-3

Yoshimura, H. (2023a, April 10). Integrative Medicine Approaches to Managing Anxiety and Depression Naturally. Retrieved from Rupa Health website: https://www.rupahealth.com/post/integrative-medicine-approaches-to-managing-anxiety-and-depression-naturally

Yoshimura, H. (2023b, May 12). Complementary and Integrative Medicine Treatment Options for PTSD Patients: Testing, Integrative Therapies, and Herbs. Retrieved from Rupa Health website: https://www.rupahealth.com/post/complementary-and-integrative-medicine-treatment-options-for-ptsd-patients-testing-integrative-therapies-and-herbs

Yoshimura, H. (2023c, June 29). Integrative Medicine Approaches to Neuropathic Pain Management: Specialty Testing and Treatment Options. Retrieved from Rupa Health website: https://www.rupahealth.com/post/integrative-approach-to-neuropathic-pain-management

Yoshimura, H. (2023d, July 27). An Integrative Medicine Approach to Treatment-Resistant Depression: Comprehensive Testing, Key Nutrients, and Complementary Therapies. Retrieved from Rupa Health website: https://www.rupahealth.com/post/an-integrative-medicine-approach-to-treatment-resistant-depression-comprehensive-testing-key-nutrients-and-complementary-therapies

Yoshimura, H. (2023e, July 27). What is Ketamine Therapy? The Process, The Risks, and Complementary Lab Testing. Retrieved December 11, 2024, from Rupa Health website: https://www.rupahealth.com/post/what-is-ketamine-therapy-the-process-the-risks-and-complementary-lab-testing

Yoshimura, H. (2023f, December 5). Harnessing the power of mind-body techniques for chronic pain management. Retrieved from Rupa Health website: https://www.rupahealth.com/post/harnessing-the-power-of-mind-body-techniques-for-chronic-pain-management

Yoshimura, H. (2023g, December 18). Exploring the Connection Between Chronic Pain and Emotional Wellbeing in Functional Medicine. Retrieved from Rupa Health website: https://www.rupahealth.com/post/exploring-the-connection-between-chronic-pain-and-emotional-wellbeing-in-functional-medicine

Yoshimura, H. (2024, January 16). Addressing Gut-Brain Connection in PTSD and Trauma Survivors through Functional Medicine. Retrieved from Rupa Health website: https://www.rupahealth.com/post/addressing-gut-brain-connection-in-ptsd-and-trauma-survivors-through-functional-medicine

Zhang, M. W. B., & Ho, R. C. M. (2016). Controversies of the Effect of Ketamine on Cognition. Frontiers in Psychiatry, 7. https://doi.org/10.3389/fpsyt.2016.00047

Order from 30+ labs in 20 seconds (DUTCH, Mosaic, Genova & More!)
We make ordering quick and painless — and best of all, it's free for practitioners.

Latest Articles

View more on Mental Health
Subscribe to the magazine for expert-written articles straight to your inbox
Join the thousands of savvy readers who get root cause medicine articles written by doctors in their inbox every week!
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Trusted Source
Rupa Health
Medical Education Platform
Visit Source
Visit Source
American Cancer Society
Foundation for Cancer Research
Visit Source
Visit Source
National Library of Medicine
Government Authority
Visit Source
Visit Source
Journal of The American College of Radiology
Peer Reviewed Journal
Visit Source
Visit Source
National Cancer Institute
Government Authority
Visit Source
Visit Source
World Health Organization (WHO)
Government Authority
Visit Source
Visit Source
The Journal of Pediatrics
Peer Reviewed Journal
Visit Source
Visit Source
CDC
Government Authority
Visit Source
Visit Source
Office of Dietary Supplements
Government Authority
Visit Source
Visit Source
National Heart Lung and Blood Institute
Government Authority
Visit Source
Visit Source
National Institutes of Health
Government Authority
Visit Source
Visit Source
Clinical Infectious Diseases
Peer Reviewed Journal
Visit Source
Visit Source
Brain
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Rheumatology
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the National Cancer Institute (JNCI)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Cardiovascular Magnetic Resonance
Peer Reviewed Journal
Visit Source
Visit Source
Hepatology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Clinical Nutrition
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Bone and Joint Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Kidney International
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Allergy and Clinical Immunology
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Chest
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Neurology, Neurosurgery & Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Blood
Peer Reviewed Journal
Visit Source
Visit Source
Gastroenterology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Respiratory and Critical Care Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Diabetes Care
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of the American College of Cardiology (JACC)
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Clinical Oncology (JCO)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Clinical Investigation (JCI)
Peer Reviewed Journal
Visit Source
Visit Source
Circulation
Peer Reviewed Journal
Visit Source
Visit Source
JAMA Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
PLOS Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Nature Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The BMJ (British Medical Journal)
Peer Reviewed Journal
Visit Source
Visit Source
The Lancet
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the American Medical Association (JAMA)
Peer Reviewed Journal
Visit Source
Visit Source
Pubmed
Comprehensive biomedical database
Visit Source
Visit Source
Harvard
Educational/Medical Institution
Visit Source
Visit Source
Cleveland Clinic
Educational/Medical Institution
Visit Source
Visit Source
Mayo Clinic
Educational/Medical Institution
Visit Source
Visit Source
The New England Journal of Medicine (NEJM)
Peer Reviewed Journal
Visit Source
Visit Source
Johns Hopkins
Educational/Medical Institution
Visit Source
Visit Source

Hey practitioners! 👋 Join Dr. Chris Magryta and Dr. Erik Lundquist for a comprehensive 6-week course on evaluating functional medicine labs from two perspectives: adult and pediatric. In this course, you’ll explore the convergence of lab results across different diseases and age groups, understanding how human lab values vary on a continuum influenced by age, genetics, and time. Register Here! Register Here.

< !--conditionally display announcement Banner-- >